Effects of Probiotic Treatment on Patients and Animals with Chronic Obstructive Pulmonary Disease: a Systematic Review and Meta-analysis of Randomized Control Trials

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2024 Sep 26

PMID 39324058

Authors

Ziying Su

Chenxi Ma

Xiaosong Ru

Sijia Zhang

Chuyi Wu

Yue Huang

Huijie Cen

Zihui Yin

Jianping Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: In recent years, the lung-gut axis has received increasing attention. The oxidative stress and systemic hypoxia occurring in chronic obstructive pulmonary disease (COPD) are related to gut dysfunction. That suggests probiotics have a potential therapeutic role in COPD. In this study, we therefore evaluated the ameliorative effects of probiotics on COPD.

Methods: Searches were conducted in four electronic databases, including PubMed, Cochrane Library, the NIH clinical registry Clinical Trials. Gov and EMBASE. The data extracted was analyzed statistically in this study using StataMP17 software, with mean difference (MD) chosen as the effect size for continuous variables, and the results expressed as effect sizes and their 95% confidence intervals (CIs). Standardized Mean Difference (SMD) was used if the data units were different.

Results: We included three randomized, controlled, double-blind clinical trials and five randomized controlled animal studies. The results show that for lung function, probiotics improved %FEV1 in COPD patients (MD = 3.02, 95%CI: 1.10, 4.93). Additionally, in inflammation, probiotics increased IL-10 (SMD = 1.99, 95%CI: 1.02, 2.96) and decreased inflammatory markers such as TNF-α (SMD= -2.64, 95%Cl: -3.38, -1.90), IL-1β (SMD= -3.49, 95%Cl: -4.58, -2.40), and IL-6 (SMD= -6.54, 95%Cl: -8.36, -4.73) in COPD animals, while having no significant effect on C-reactive protein (MD = 0.30, 95%CI: -0.71, 1.32) in COPD patients. For lung structure, probiotics significantly reduced the degree of pulmonary collagen fibers deposition in COPD animals (SMD = -2.25, 95%CI: -3.08, -1.41).

Conclusion: Overall, probiotics may be an additional approach that can improve COPD. Further clinical trials are needed to evaluate the efficacy, safety, and impact factors of probiotics for COPD.

Systematic Review Registration: https://inplasy.com/inplasy-2023-4-0023/, identifier INPLASY202340023.

References

Hao R, Liu Q, Wang L, Jian W, Cheng Y, Zhang Q . Anti-inflammatory effect of T1 cell-free supernatants through suppression of oxidative stress and NF-κB- and MAPK-signaling pathways. Appl Environ Microbiol. 2023; 89(10):e0060823. PMC: 10617582. DOI: 10.1128/aem.00608-23. View

Yanbaeva D, Dentener M, Spruit M, Houwing-Duistermaat J, Kotz D, Passos V . IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. BMC Med Genet. 2009; 10:23. PMC: 2660301. DOI: 10.1186/1471-2350-10-23. View

Celli B, Wedzicha J . Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med. 2019; 381(13):1257-1266. DOI: 10.1056/NEJMra1900500. View

Sa A, Olimpio F, Vasconcelos J, Rosa P, Faria Neto H, Rocha C . Involvement of GPR43 Receptor in Effect of on Murine Steroid Resistant Chronic Obstructive Pulmonary Disease: Relevance to Pro-Inflammatory Mediators and Oxidative Stress in Human Macrophages. Nutrients. 2024; 16(10). PMC: 11124176. DOI: 10.3390/nu16101509. View

Qu L, Cheng Q, Wang Y, Mu H, Zhang Y . COPD and Gut-Lung Axis: How Microbiota and Host Inflammasome Influence COPD and Related Therapeutics. Front Microbiol. 2022; 13:868086. PMC: 9012580. DOI: 10.3389/fmicb.2022.868086. View

Song L, Xu M, Zhou X, Zhang D, Zhang S, Zheng G . A Preclinical Systematic Review of Ginsenoside-Rg1 in Experimental Parkinson's Disease. Oxid Med Cell Longev. 2017; 2017:2163053. PMC: 5366755. DOI: 10.1155/2017/2163053. View

Olimpio F, Andreata-Santos R, Rosa P, Santos W, Oliveira C, Aimbire F . Lactobacillus rhamnosus Restores Antiviral Signaling and Attenuates Cytokines Secretion from Human Bronchial Epithelial Cells Exposed to Cigarette Smoke and Infected with SARS-CoV-2. Probiotics Antimicrob Proteins. 2022; 15(6):1513-1528. PMC: 9643982. DOI: 10.1007/s12602-022-09998-2. View

. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020; 8(6):585-596. PMC: 7284317. DOI: 10.1016/S2213-2600(20)30105-3. View

Bikov A, Dragonieri S, Csoma B, Mazzuca C, Finamore P, Rocchi G . The Role of Gut Bacteriome in Asthma, Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnoea. Microorganisms. 2022; 10(12). PMC: 9781820. DOI: 10.3390/microorganisms10122457. View

10.

Shi J, Luo D, Weng H, Zeng X, Lin L, Chu H . Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020; 11(5):641-654. DOI: 10.1002/jrsm.1429. View

11.

Wang H, Wang L, Xie Z, Zhou S, Li Y, Zhou Y . Nitric Oxide (NO) and NO Synthases (NOS)-Based Targeted Therapy for Colon Cancer. Cancers (Basel). 2020; 12(7). PMC: 7408898. DOI: 10.3390/cancers12071881. View

12.

Panahi Y, Ghanei M, Vahedi E, Mousavi S, Imani S, Sahebkar A . Efficacy of probiotic supplementation on quality of life and pulmonary symptoms due to sulfur mustard exposure: a randomized double-blind placebo-controlled trial. Drug Chem Toxicol. 2016; 40(1):24-29. DOI: 10.3109/01480545.2016.1166250. View

13.

Bulanda E, Wypych T . Bypassing the Gut-Lung Axis Microbial Metabolites: Implications for Chronic Respiratory Diseases. Front Microbiol. 2022; 13:857418. PMC: 9113535. DOI: 10.3389/fmicb.2022.857418. View

14.

Luo D, Wan X, Liu J, Tong T . Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2016; 27(6):1785-1805. DOI: 10.1177/0962280216669183. View

15.

Xie C, Pan J, Zhang S, Gan J, Liu Z . Effect of nicotine on L-dopa-induced dyskinesia in animal models of Parkinson's disease: a systematic review and meta-analysis. Neurol Sci. 2014; 35(5):653-62. DOI: 10.1007/s10072-014-1652-5. View

16.

Qin D, Ma Y, Wang Y, Hou X, Yu L . Contribution of on Intestinal Mucosal Barrier and Diseases: Perspectives and Challenges of . Life (Basel). 2022; 12(11). PMC: 9696601. DOI: 10.3390/life12111910. View

17.

Park S, Saiphoklang N, Phillips J, Wilgus M, Buhr R, Tashkin D . Three-Month Variability of Commonly Evaluated Biomarkers in Clinically Stable COPD. Int J Chron Obstruct Pulmon Dis. 2023; 18:1475-1486. PMC: 10362903. DOI: 10.2147/COPD.S396549. View

18.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

19.

Peng L, Li Z, Green R, Holzman I, Lin J . Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009; 139(9):1619-25. PMC: 2728689. DOI: 10.3945/jn.109.104638. View

20.

Lai H, Lin T, Chen T, Kuo Y, Chang C, Wu T . Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory lipopolysaccharide. Gut. 2021; 71(2):309-321. DOI: 10.1136/gutjnl-2020-322599. View